Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Gazda

Psychiatry Phoenix, AZ Medical Doctor

NPI 1730158189 CMS profile 351454

3033 N Central Ave Ste 700, Phoenix, AZ 85012

Open in the dashboard

General payments

$714,410

988 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Gazda of Phoenix, AZ is reported in the CMS Open Payments database as having received $714,410 across 988 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53,799 47
2024 General $117,875 139
2023 General $207,098 299
2022 General $131,048 221
2021 General $27,517 60
2020 General $41,449 50
2019 General $135,625 172

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Gazda
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Thomas Gazda were reported at $53,799. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Thomas Gazda Psychiatry median Middle half National median
2019 $135,625 $184 $59–$605 $163
2020 $41,449 $119 $36–$372 $114
2021 $27,517 $143 $43–$576 $132
2022 $131,048 $153 $50–$590 $149
2023 $207,098 $170 $56–$651 $160
2024 $117,875 $179 $57–$673 $164
2025 $53,799 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $268,832 309 payments
  2. Janssen Pharmaceuticals, Inc $187,610 266 payments
  3. Teva Pharmaceuticals USA, Inc. $73,892 86 payments
  4. Axsome Therapeutics, Inc. $71,585 73 payments
  5. E.R. Squibb & Sons, L.L.C. $58,078 58 payments
  6. ITI, Inc. $23,816 31 payments
  7. BioXcel Therapeutics, Inc. $20,505 57 payments
  8. Idorsia Pharmaceuticals US Inc $6,346 12 payments
  9. Luye Pharma (USA) Ltd. $1,750 1 payment
  10. AbbVie, Inc. $717 40 payments
  11. Other $1,279 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $527,979 206 payments
  2. Travel and Lodging $94,267 348 payments
  3. Consulting Fee $51,606 14 payments
  4. Honoraria $20,988 6 payments
  5. Food and Beverage $19,479 412 payments
  6. Education $91 2 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $165,966 225 payments
  2. INVEGA TRINZA $163,640 207 payments
  3. ARISTADA Cns $152,615 175 payments
  4. ARISTADA Cns $152,615 175 payments
  5. ARISTADA INITIO $152,570 173 payments
  6. ARISTADA Cns $152,569 173 payments
  7. ARISTADA Cns $152,569 173 payments
  8. LYBALVI Cns $116,241 136 payments
  9. LYBALVI Cns $116,196 134 payments
  10. LYBALVI Cns $116,149 132 payments
  11. Other $364,442 551 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$2,934

Medicare's payments for the services billed

Medicare patients

20

Average age 44

Services billed

53

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Depression 55%
Cancer 0%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
$32,286 — —
INVEGA SUSTENNA
$17,791 — —
INVEGA TRINZA
$17,386 — —
UZEDY
$11,745 — —
LYBALVI
$7,742 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

988 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record